ClinicalTrials.gg
Not yet recruitingNCT07274137Updated Dec 22, 2025

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)

A Phase 3 interventional study of MDR-001 and Placebo in Overweight or Obesity, sponsored by MindRank AI Ltd. Not yet recruiting at 45 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MindRank AI Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
738
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
51st of 502
738 · median 120
Started
2026
with 133 others
Phase 3
100 of 600
50 open now
Primary completion
2027-06
later than 169 of 280 live
Registered
432nd of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 51st largest by planned enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 100 in phase 3, reaches primary completion later than 169 of the 280 other live ones, and was the 432nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 738 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

MindRank AI Ltd is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have given written to participate in this study
  • Chinese male or female participants who are aged 18-65 (inclusive) years at the time of signing the ICF
  • Participants who are obesity ( ≥ 28.0 kg/m2), or overweight (24.0 kg/m2 ≤ BMI \< 28.0 kg/m2) with at least one of the the following weight-related comorbidities at screening:1) Pre-diabetes. 2) Hypertension.3) Dyslipidemia.4) Fatty liver.5) Obstructive sleep apnea syndrome.6) Complaint of weight-bearing joint pain.
  • Participants had a stable weight maintenance during the 3 months of dietary and physical activity prior to screening (participant-reported data acceptable) and no more than 5% weight fluctuation

Exclusion criteria

Exclusion Criteria:

  • Obesity induced by secondary diseases or drug
  • Have diabetes mellitus
  • Have any lifetime history of a suicidal attempt or suicidal behavior
  • Have a history of depressive disorder
  • History of gout within 6 months prior to screening
  • History of major cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as:1)Acute myocardial infarction (MI), percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), heart valve repair/replacement, unstable angina, hemorrhagic stroke (stroke), ischemic stroke (including [TIA]).2)Congestive heart failure of (NYHA) class III or IV.3)Severe arrhythmias
  • History of within 5 years prior to screening or newly diagnosed malignancy at screening
  • Have a family or personal history (parents, children, and siblings of medullary thyroid cancer or Multiple Endocrine Neoplasia Syndrome Type 2 .
  • Abnormal thyroid function tests at screening not adequately controlled by stable medication doses , or thyroid ultrasound at screening showing thyroid nodules classified as Chinese-thyroid imaging-reporting and data system category 4 or higher.
  • History of significant gastrointestinal disease or gastrointestinal surgery or gastric emptying abnormality within 6 months prior to screening.
  • History of intestinal disorders deemed clinically significant by the investigator, or acute hemorrhoidal episode within 3 months prior to screening.
  • History of acute or chronic pancreatitis, or abnormally elevated serum amylase or lipase levels at screening.
  • revious acute or chronic hepatitis, or symptoms and signs of any other liver disease other than non-alcoholic fatty liver disease, or abnormalities in related laboratory tests at screening
  • Presence of acute or chronic cholecystitis at screening, or symptomatic or treatment-requiring cholelithiasis/gallbladder polyps at screening, or newly diagnosed cholelithiasis within 6 months before screening
  • or suspected hypersensitivity to glucagon-like peptide 1 receptor agonist (GLP-1RA) drugs or .
  • History of drug abuse or dependence prior to screening.
  • Have current or history of treatment with medications that may cause significant weight gain within 3 months prior to screening, including but not limited to:

    1. Approved/unapproved marketed weight-loss drugs: orlistat, sibutramine hydrochloride, phentermine, phentermine-topiramate, naltrexone-amfebutamone, tirzepatide, semaglutide, liraglutide, beinaglutide, phendimetrazine, methylamphetamine, etc.
    2. products of weight-loss: Glucagon-like peptide 1 receptor (GLP-1R) agonists, GLP-1R/glucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonists, GIPR/GLP-1R/GCGR agonists,GLP-1R agonists/activin type II receptor (ActRII) inhibitors, GLP-1R/GIPR/fibroblast growth factor 21 receptor (FGF21R) agonists or FGF21R/GCGR/GLP-1R agonists.
    3. Hypoglycemic drugs, such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones (TZDs) or dipeptidyl peptidase 4 (DPP-4) inhibitors.
    4. Systemic therapy (including intravenous, oral, intra-articular).
    5. Tricyclic antidepressants or other antipsychotic or antiepileptic drugs affecting body weight (e.g., mirtazapine, paroxetine, clozapine, olanzapine, risperidone, quetiapine, paliperidone, valproic acid, valproic acid derivatives, lithium).
  • History of bariatric surgery (excluding acupuncture/cupping/catgut embedding for bariatric surgery, liposuction, and abdominoplasty performed >1 year prior to screening) or plans to undergo bariatric surgery or acupuncture/cupping/catgut embedding, liposuction, abdominoplasty during the study period.
  • Planned chronic use of medications affecting gastrointestinal motility or scheduled gastric emptying-impairing surgery during the study period.
  • Major or medium-sized surgery, or severe trauma or serious infection within 3 months prior to screening, which, as assessed by the investigator, would preclude trial participation, or planned surgery during the study period (excluding outpatient procedures deemed by the investigator to have no impact on subject safety or trial outcomes).
  • History of organ transplant.
  • Use of any drug or food known to potently or moderately inhibit or induce cytochrome P450 3A4 enzyme () and/or inhibit P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study.
  • Currently participating in any other clinical study, or if received any investigational product or medical devices within ≤ 3 months or 5 half-lives (t1/2) prior to screening, whichever is longer.
  • Donation or loss of ≥ 400 mL of blood or transfusion/blood products during this period within 3 months prior to screening, or intention to donate blood during the study.
  • emale participants during pregnancy or lactation.
  • The investigator, site personnel, and/or their immediate family members directly related to the study. An immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  • Participants who may be unable to complete this study for other reasons, or have other conditions that, as assessed by the investigator, will make the participant unsuitable for participation in this study, for example, the participant refuses to use only the weight-loss drugs specified in the protocol during the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
738 participants (estimated)

Study arms

  • Experimental
    MDR-001 Dose 1

    Drug: MDR-001

  • Experimental
    MDR-001 Dose 2

    Drug: MDR-001

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • Participants will Receive Small Molecule MDR-001 Tablets Administered Orally

  • DrugPlacebo

    Participants will Receive Placebo

07

What researchers measure

Primary outcomes

  1. Percentage change from baseline in body weight (%) at Week 52

    (Week 52 body weight-baseline body weight)/baseline weight

    Time frame: baseline,Week 52

  2. Percentage (%) of participants who achieve≥5% body weight reduction from baseline at Week 52

    (Week 52 body weight-baseline body weight)/baseline body weight, who achieve≥5%

    Time frame: baseline,Week 52

Secondary outcomes

  1. Change from baseline in body weight (kg) at Week 52

    Week 52 body weight-baseline body weight

    Time frame: baseline,Week 52

  2. Percentage (%) of participants who achieve ≥ 10% or ≥ 15% body weight reduction from baseline at Week 52

    (Week 52 body weight-baseline body weight)/baseline body weight, who achieve≥ 10% or ≥ 15%

    Time frame: Baseline,Week52

  3. Change from baseline in BMI (kg/m2) at Week 52

    BMI (kg/m2) = weight (kg)/height (m)2

    Time frame: Baseline,Week52

  4. Change from baseline in waist circumference (cm) at Week 52

    Week 52 waist circumference-baseline waist circumference

    Time frame: Baseline, Week52

  5. Change from baseline in hip circumference (cm) at Week 52

    Week 52 hip circumference-baseline hip circumference

    Time frame: Baseline,Week 52

  6. Change from baseline in waist-hip ratio (%) at Week 52

    Waist-to-hip ratio = waist circumference (cm) / hip circumference (cm)

    Time frame: Baseline,Week52

  7. Change from baseline in Total cholesterol (TC, mmol/L) at Week 52

    Week 52 Total cholesterol-baseline Total cholesterol

    Time frame: Baseline, Week 52

  8. Change from baseline in Triglycerides (TG, mmol/L) at Week 52

    Week 52 Triglycerides-baseline Triglycerides

    Time frame: baseline,Week 52

  9. Change from baseline in Low-density lipoprotein cholesterol (LDL-C, mmol/L) at Week 52

    Week 52 Low-density lipoprotein cholesterol-baseline Low-density lipoprotein cholesterol

    Time frame: baseline,Week 52

  10. Change from baseline in High-density lipoprotein cholesterol (HDL-C,mmol/L) at Week 52

    Week 52 High-density lipoprotein cholesterol-baseline High-density lipoprotein cholesterol

    Time frame: baseline,Week 52

  11. Change from baseline in Non-high-density lipoprotein cholesterol (nHDL-C, mmol/L) at Week 52

    Week 52 Non-high-density lipoprotein cholesterol-baseline Non-high-density lipoprotein cholesterol

    Time frame: baseline,Week 52

  12. Change from baseline in Lipoprotein (a) (Lp[a], mg/dL) at Week 52

    Week 52 Lipoprotein -baseline Lipoprotein

    Time frame: baseline,Week 52

  13. Change from baseline in Systolic blood pressure (SBP, mmHg) at Week 52

    Week 52 Systolic blood pressure-baseline Systolic blood pressure

    Time frame: baseline,Week 52

  14. Change from baseline in Diastolic blood pressure (DBP, mmHg) at Week 52

    Week 52 Diastolic blood pressure-baseline Diastolic blood pressure

    Time frame: baseline,Week 52

  15. Change from baseline in Glycosylated hemoglobin (HbA1c, %) at Week 52

    Week 52 Glycosylated hemoglobin-baseline Glycosylated hemoglobin

    Time frame: baseline,Week 52

  16. Change from baseline in Fasting plasma glucose (FPG, mmol/L) at Week 52

    Week 52 Fasting plasma glucose-baseline Fasting plasma glucose

    Time frame: baseline,Week 52

  17. Adverse events

    Number of participants with treatment-related adverse events as assessed by mild, moderate and severe

    Time frame: baseline,Week 52

08

Study locations

45 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2027, 16 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 16 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 10, 2025
StartEst.
Feb 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07274137
Lead sponsor
MindRank AI Ltd
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Feb 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Wei N Jia
Contact
weina.jia@mindrank.cn
18019055108

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MDR-001

Start the discussion